Akèy › Kansè poumon › Kalifòni › Mountain View
Etid klinik pou Kansè poumon nan Mountain View, CA
17 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Mountain View (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi lwen
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi lwen
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Ap rekriteFaz 3
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi lwen
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Ap rekriteFaz 2
- Stanford Cancer Institute, Stanford · 5 mi lwen
- Stanford Hospital and Clinics, Stanford · 5 mi lwen
- Stanford Hospital Investigational Drug Services, Stanford · 5 mi lwen
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford · 5 mi lwen
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Palo Alto Medical Foundation Research Center, Palo Alto · 5 mi lwen
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi lwen
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford · 5 mi lwen
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Ap rekrite
- VA Palo Alto Health Care System, Palo Alto · 5 mi lwen
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Ap rekriteEtid obsèvasyon
- Stanford University School of Medicine, Stanford · 5 mi lwen
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- Stanford University - Stanford Cancer Institute, Stanford · 5 mi lwen
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Stanford University, Stanford · 5 mi lwen
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Ap rekriteFaz 1/2
- Stanford University, Stanford · 5 mi lwen
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Ap rekriteFaz 1
- Stanford University, Palo Alto · 5 mi lwen
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
Ap rekriteVolontè an sante akeyi
- Standard University, Stanford · 5 mi lwen
Engagement of Veterans With Lung Cancer
Ap rekrite
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · 5 mi lwen
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Ap rekriteFaz 1/2
- Stanford University, School of Medicine, Palo Alto · 5 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Stanford · 5 mi lwen
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Arlington, VA41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Mountain View
- Kansè (tout kalite)40 etid
- Kansè nan tete25 etid
- Kansè Metastatik25 etid
- Kansè Poumon ki pa ti selil21 etid
- Leksemi mieloïd egi19 etid
- Kansè ovè19 etid
- Twoub Spektòm Otis17 etid
- Ensifizyans kadyak15 etid
- Kansè pwostat15 etid
- Otis13 etid
- Leksemi limfoblastik egi13 etid
- Kansè kolorektal13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.